Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BCTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsBriaCell files routine Q2 2026 financials via Canadian subsidiary disclosure
Filed March 31, 2026 · Period ending March 31, 2026 · ~1 min read
Key Changes
-
low
BriaPro Therapeutics, BriaCell's subsidiary, filed unaudited financial statements and management discussion for the three and six months ended January 31, 2026 with British Columbia and Alberta securities regulators.
Item 8.01 view on EDGAR → -
low
Filing made under Regulation FD to ensure U.S. investors have access to the same quarterly financial information disclosed in Canada.
8-K: Reg FD Disclosure view on EDGAR →
Summary
BriaCell Therapeutics filed a routine 8-K to disclose that its subsidiary BriaPro Therapeutics submitted unaudited Q2 fiscal 2026 financial statements and management's discussion and analysis to Canadian provincial securities regulators. The documents cover the three and six month periods ending January 31, 2026. This is a procedural compliance filing under Regulation FD, ensuring U.S. investors receive the same quarterly financial information that was filed with Canadian authorities.
For retail holders, this represents standard quarterly reporting with no material business developments announced. The actual financial performance details would be found in the attached exhibits. Investors should review the filed financials and MD&A for operational updates and cash position, particularly given BriaCell's status as a clinical-stage biotech company.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On March 31, 2026, BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp. (the “Company”), filed its unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three and six month period ended January 31, 2026, with the British Columbia Securities Commission and Alberta Securities Commission.
The company disclosed that its subsidiary BriaPro filed unaudited interim financials and MD&A covering the three and six months ended January 31, 2026 with Canadian provincial securities regulators. These documents are attached as exhibits to this 8-K filing. This is a routine Regulation FD disclosure ensuring U.S. investors have access to the same financial information filed in Canada.
Event · Item 9.01 — Financial Statements and Exhibits
BriaCell filed Q2 FY2026 financials and MD&A for the period ended January 31, 2026.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three and six month period ended January 31, 2026.
The company disclosed unaudited condensed interim consolidated financial statements covering the three and six month periods ended January 31, 2026. This is a routine quarterly financial disclosure required for public companies.
Added in current filing · verify on EDGAR →
BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the three and six month period ended January 31, 2026.
The company filed Management's Discussion and Analysis for the three and six month periods ended January 31, 2026. This document provides management's perspective on financial condition and results of operations for the quarter.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify